日报更新时间：
周报更新时间：04-11 03:39
今开价：7.85
最高价：7.85
成交量：1355136.0
昨收价：7.85
最低价：7.44
最新价：7.56
英文名称：Immunogen
行业：医疗
简介：ImmunoGen, Inc.于1981年在马萨诸塞州组成，专注于基于抗体的抗癌疗法的研发.该公司利用其专有的抗体药物共轭技术和ADC技术治疗癌症
电话：1-781-8950600
ImmunoGen免疫原公司是一家生物技术公司，开发有针对性的抗癌疗法，利用抗体-药物偶联技术开发产品，并通过抗体-药物偶联药物对HER2阳性转移性乳腺癌的进行治疗。另外，ImmunoGen还为罗氏提供Kadcyla特许权使用权（收取使用费）。ImmunoGen公司主要产品： IMGN853 - I期临床试验阶段，对卵巢癌，子宫内膜癌和其它癌症进行治疗 IMGN289 - I期临床试验阶段，对脑癌、肩颈癌以及非小细胞肺癌、鳞状细胞癌的治疗 IMGN529 - I期临床试验阶段，对淋巴瘤、慢性淋巴细胞白血病进行治疗 IMGN779 - 在临床前阶段，用于治疗急性髓细胞性白血病 AMG172 - I期临床试验阶段，肾透明细胞癌的治疗（化合物） AMG595 - I期临床试验阶段，用于治疗成胶质细胞瘤（化合物） BAY94-9343 - 早期临床阶段，用于间皮瘤和卵巢癌的治疗 BT-062 - 多发性骨髓瘤治疗 SAR3419 - II期临床试验，用于弥漫性大B细胞淋巴瘤的治疗 SAR650984 - 早期临床试验，用于治疗多发性骨髓瘤 SAR566658 - I期临床试验，用于治疗CA6阳性实体瘤 SAR408701 - 治疗固体肿瘤
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-06-30 | Barrows (Craig) | General Counsel | Buy | 5230 | 1.84 |
| 2019-06-30 | Ryll (Thomas) | Officer | Buy | 5230 | 1.84 |
| 2019-06-30 | Berkenblit (Anna) | Officer | Buy | 5230 | 1.84 |
| 2019-06-30 | Mckee (Blaine H Ph.D.) | Officer | Buy | 5230 | 1.84 |
| 2019-06-30 | Foster David G | Officer | Buy | 3536 | 1.84 |
| 2019-06-30 | Enyedy (Mark J) | Chief Executive Officer | Buy | 5230 | 1.84 |
| 2019-01-06 | Gregory (Richard J) | Officer | Sell | 3038 | 5.27 |
| 2019-01-02 | Ryll (Thomas) | Officer | Buy | 2455 | 4.08 |
| 2019-01-02 | Enyedy (Mark J) | Chief Executive Officer | Buy | 2455 | 4.08 |
| 2019-01-02 | Foster David G | Officer | Buy | 1472 | 4.08 |
| 2019-01-02 | Barrows (Craig) | General Counsel | Buy | 2455 | 4.08 |
| 2019-01-02 | Berkenblit (Anna) | Officer | Buy | 2455 | 4.08 |
| 2019-01-02 | Wingrove Theresa G | Officer | Buy | 2244 | 4.08 |
| 2018-11-05 | Goldberg (Mark Alan) | Director | Buy | 30000 | 5.76 |
| 2018-10-15 | Berkenblit (Anna) | Officer | Sell | 5851 | 8.00 |
| 2018-09-09 | Berkenblit (Anna) | Officer | Sell | 5851 | 9.46 |
| 2018-06-05 | Johnston David Brannon | Chief Financial Officer | Buy | 10000 | 3.05 |
| 2018-06-05 | Johnston David Brannon | Chief Financial Officer | Sell | 10000 | 11.02 |
| 2018-03-15 | Junius (Daniel M) | Director | Sell | 25000 | 12.02 |
| 2018-03-15 | Junius (Daniel M) | Director | Buy | 25000 | 4.29 |
| 2018-03-14 | Johnston David Brannon | Chief Financial Officer | Sell | 10000 | 11.53 |
| 2018-03-14 | Johnston David Brannon | Chief Financial Officer | Buy | 10000 | 3.05 |
| 2018-02-21 | Ryll (Thomas) | Officer | Sell | 11495 | 5.60 |
| 2018-02-21 | Berkenblit (Anna) | Officer | Sell | 16562 | 5.60 |
| 2018-02-21 | Wingrove Theresa G | Officer | Sell | 11032 | 5.60 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| FMR Inc | 1696894 | 1.13% | -4731090 | -73.60% | 2019-03-31 |
| BlackRock Fund Advisors | 6599563 | 4.40% | 27931 | 0.43% | 2019-07-31 |
| Renaissance Technologies Corp | 7043640 | 4.71% | 861500 | 13.94% | 2019-03-31 |
| ClearBridge Advisors, LLC | 8870628 | 5.93% | 464147 | 5.52% | 2019-03-31 |
| SSGA Funds Management Inc | 10228806 | 6.82% | -11460 | -0.11% | 2019-07-31 |
| Vanguard Group Inc | 10529150 | 7.04% | 36927 | 0.35% | 2019-03-31 |
| BlackRock Inc | 12316896 | 8.24% | -61308 | -0.50% | 2019-03-31 |
| State Street Corporation | 12647744 | 8.46% | 4547373 | 56.14% | 2019-03-31 |
| Redmile Group, LLC | 13063767 | 8.74% | 2179160 | 20.02% | 2019-03-31 |
| PRIMECAP Management Company | 3757600 | 2.51% | -7400 | -0.20% | 2019-03-31 |
| Morgan Stanley - Brokerage Accounts | 3340830 | 2.23% | -2019368 | -37.67% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 3329732 | 2.22% | 561489 | 20.28% | 2019-07-31 |
| Northern Trust Corp | 1769126 | 1.18% | -4647 | -0.26% | 2019-03-31 |
| Northern Trust Investments N A | 1769126 | 1.18% | -4647 | -0.26% | 2019-03-31 |
| Geode Capital Management, LLC | 1864609 | 1.25% | -1570931 | -45.73% | 2019-03-31 |
| Bank of America Corporation | 1870390 | 1.25% | 1075483 | 135.30% | 2019-03-31 |
| Fidelity Management & Research Company | 2022035 | 1.35% | -2004634 | -49.78% | 2019-07-31 |
| T. Rowe Price Associates, Inc. | 2440764 | 1.63% | 103471 | 4.43% | 2019-03-31 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 2793351 | 1.87% | -813373 | -22.55% | 2019-03-31 |
| Northern Trust Investments Inc | 2801556 | 1.87% | 2214 | 0.08% | 2019-07-31 |
| Fidelity Management and Research Company | 1696894 | 1.13% | -4710690 | -73.52% | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 3356668 | 2.24% | -135 | -- | 2019-05-31 |
| Millennium Management LLC | 4389260 | 2.94% | 3552118 | 424.31% | 2018-12-31 |
| ING Investment Management LLC | 2232721 | 1.49% | -191296 | -7.89% | 2018-12-31 |
| Point72 Asset Management, L.P. | 2654299 | 1.78% | -3518466 | -57.00% | 2018-12-31 |
| Fidelity SelectCo, LLC | 3905359 | 2.61% | -1217659 | -23.77% | 2019-03-31 |
| Citadel Advisors Llc | 2305676 | 1.54% | 437848 | 23.44% | 2018-09-30 |
| TIAA-CREF Investment Management LLC | 2405904 | 1.61% | 1210268 | 101.22% | 2018-09-30 |
| Teachers Advisors LLC | 4890042 | 3.28% | 2595252 | 113.09% | 2018-09-30 |
| Capital Research Global Investors | 7095570 | 4.76% | -2335430 | -24.76% | 2018-09-30 |
| Capital Research and Management Company | 6145570 | 4.12% | -2335430 | -27.54% | 2018-12-31 |
| Orbimed Advisors, LLC | 2904270 | 1.95% | 1400000 | 93.07% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 3941530 | 2.64% | 980855 | 33.13% | 2018-06-30 |
| State Street Corp | 8996007 | 6.04% | 1758759 | 24.30% | 2018-06-30 |
| Morgan Stanley & Co Inc | 2709638 | 1.82% | 1608293 | 146.03% | 2018-06-30 |
| Teachers Advisors Inc | 2294790 | 1.54% | 1133730 | 97.65% | 2018-06-30 |
| Franklin Advisers Inc | 1737000 | 1.17% | -935400 | -35.00% | 2018-06-30 |
| Goldman, Sachs & Co. | 1519235 | 1.02% | 604541 | 66.09% | 2018-06-30 |
| Pinnacle Associates Inc | 1267507 | 0.95% | -54724 | -4.14% | 2018-03-31 |
| Wells Fargo Advisors, LLC | 1365331 | 1.03% | -39627 | -2.82% | 2018-03-31 |
| Delaware Management Business Trust | 1130000 | 0.85% | -- | -- | 2018-03-31 |
| Baker Bros Advisors LP | 2563489 | 1.93% | -125000 | -4.65% | 2017-12-31 |
| Morgan Stanley & Co International PLC | 1142300 | 0.86% | 1142300 | -- | 2017-12-31 |
| Invesco PowerShares Capital Mgmt LLC | 1058198 | 0.80% | 583800 | 123.06% | 2017-12-31 |
| Fundlogic SAS | 997645 | 0.75% | 997645 | -- | 2017-12-31 |
| Panagora Asset Management Inc | 919509 | 0.80% | -633629 | -40.80% | 2017-09-30 |
| Morgan Stanley Smith Barney LLC | 871348 | 0.75% | -26570 | -2.96% | 2017-09-30 |
| Delaware Management Company | 1130000 | 0.85% | -- | -- | 2018-01-31 |
| Managed Account Advisors LLC | 1689384 | 1.46% | 564893 | 50.24% | 2017-09-30 |
| Close Finsbury Asset Management Limited | 825929 | 0.93% | 56581 | 7.35% | 2017-10-31 |
| Arrowstreet Capital Limited Partnership | 817616 | 0.71% | 803216 | 5577.89% | 2017-09-30 |
| Raymond James & Associates | 657202 | 0.75% | 10762 | 1.66% | 2016-09-30 |
| Deutsche Bank AG | 1274733 | 1.46% | 69507 | 5.77% | 2016-09-30 |
| The Vanguard Group | 5310180 | 9.00% | 74342520 | 0.10% | 1999-11-30 |
| BlackRock,Inc. | 5960625 | 9.00% | 83448750 | 0.10% | 1999-11-30 |
| FMR LLC | 9416760 | 9.00% | 131834640 | 0.10% | 1999-11-30 |
| ClearBridge Investments,LLC | 13500010 | 9.00% | 189000140 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity | 586584 | 0.39% | 75568 | 14.79% | 2019-04-30 |
| Vanguard Strategic Equity Fund | 1121434 | 0.75% | -189472 | -14.45% | 2019-03-31 |
| iShares Nasdaq Biotechnology ETF | 1491138 | 0.99% | 26767 | 1.83% | 2019-07-30 |
| Meridian Small Cap Growth Fund | 1523553 | 1.02% | -169439 | -10.01% | 2019-03-31 |
| Vanguard Extended Market Index Fund | 2090792 | 1.39% | -5225 | -0.25% | 2019-06-30 |
| PrimeCap Odyssey Growth Fund | 2400000 | 1.60% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 3271748 | 2.18% | 6402 | 0.20% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 3290639 | 2.20% | 561716 | 20.58% | 2019-06-30 |
| SPDR | 10082534 | 6.73% | -9868 | -0.10% | 2019-06-21 |
| Direxion Daily S&P Biotech Bull 3X Shrs | 991917 | 0.66% | 269152 | 37.24% | 2019-04-30 |
| Candriam Eqs L Biotechnology | 912500 | 0.61% | -100000 | -9.88% | 2019-06-30 |
| NT R2000 Growth Index Fund - Non-Lending | 589034 | 0.39% | -32493 | -5.23% | 2019-06-30 |
| iShares Russell 2000 Value ETF | 589760 | 0.39% | 1194 | 0.20% | 2019-07-31 |
| State Street Russell Small Cap | 600952 | 0.40% | -- | -- | 2019-07-31 |
| State Street Russell Small/Mid Cap | 649698 | 0.43% | 48800 | 8.12% | 2019-07-31 |
| iShares Russell 2000 Growth ETF | 724343 | 0.48% | -- | -- | 2019-07-30 |
| Vanguard Explorer Fund | 823076 | 0.55% | -- | -- | 2019-03-31 |
| Vanguard Strategic Small Cap Equity Fund | 854990 | 0.57% | -- | -- | 2019-03-31 |
| Vanguard Capital Opportunity Fund | 863800 | 0.58% | -- | -- | 2019-03-31 |
| TIAA-CREF Quant Small-Cap Equity Fund | 961600 | 0.64% | -15300 | -1.57% | 2019-05-31 |
| T. Rowe Price New Horizons Fund | 656590 | 0.44% | 92090 | 16.31% | 2019-03-31 |
| T. Rowe Price Health Sciences Fund | 870241 | 0.58% | 41508 | 5.01% | 2019-03-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 2914220 | 1.95% | -4887 | -0.17% | 2019-05-30 |
| PGIM Jennison Health Sciences Fund | 720106 | 0.48% | -- | -- | 2019-04-30 |
| Meridian Contrarian Fund | 675000 | 0.45% | 675000 | -- | 2018-12-31 |
| Delaware Healthcare Fund | 650000 | 0.44% | -- | -- | 2019-01-31 |
| Voya SmallCap Opportunities Fund | 656815 | 0.44% | 157922 | 31.65% | 2018-09-30 |
| Parvest Equity USA Small Cap | 659329 | 0.44% | -5795 | -0.87% | 2018-11-30 |
| American Funds SMALLCAP World Fund | 5433000 | 3.64% | -2000000 | -26.91% | 2018-09-30 |
| American Funds IS | 712570 | 0.48% | -335430 | -32.01% | 2018-09-30 |
| TIAA-CREF Growth & Income Fund | 954482 | 0.64% | -1800 | -0.19% | 2018-10-31 |
| VA CollegeAmerica SMALLCAP Wld Fd | 5433000 | 3.64% | -2000000 | -26.91% | 2018-09-30 |
| Franklin Biotechnology Discovery Fund | 1076400 | 0.72% | -- | -- | 2018-06-30 |
| iShares Nasdaq Biotechnology | 1692315 | 1.04% | -3222 | -0.19% | 2018-09-12 |
| Vanguard Explorer Inv | 823076 | 0.55% | -440515 | -34.86% | 2018-06-30 |
| T. Rowe Price New Horizons | 846900 | 0.57% | 89800 | 11.86% | 2018-06-30 |
| Fidelity VIP Mid Cap Inv | 886500 | 0.59% | 886500 | -- | 2018-07-31 |
| Vanguard Capital Opportunity Inv | 898300 | 0.60% | -- | -- | 2018-06-30 |
| VA CollegeAmerica Smcap World 529E | 7433000 | 4.99% | 7433000 | -- | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 3661203 | 2.46% | -- | -- | 2018-07-31 |
| PRIMECAP Odyssey Growth | 2400000 | 1.61% | -- | -- | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 1942570 | 1.30% | 7500 | 0.39% | 2018-07-31 |
| iShares Russell 2000 Growth | 1263014 | 0.78% | -1218 | -0.10% | 2018-09-12 |
| Delaware Healthcare A | 1130000 | 0.76% | -- | -- | 2018-07-31 |
| CREF Stock R1 | 1123254 | 0.75% | -6913 | -0.61% | 2018-07-31 |
| Vanguard Strategic Small-Cap Equity Inv | 905546 | 0.61% | -- | -- | 2018-06-30 |
| Fidelity Advisor | 951156 | 0.64% | -1639103 | -63.28% | 2018-07-31 |
| TIAA-CREF Growth & Income Instl | 976082 | 0.65% | -4700 | -0.48% | 2018-07-31 |
| TIAA-CREF Small-Cap Equity Instl | 1017500 | 0.68% | 68700 | 7.24% | 2018-07-31 |
| Vanguard Strategic Equity Inv | 1008030 | 0.68% | 308396 | 44.08% | 2018-06-30 |
| Prudential Jennison Health Sciences A | 720106 | 0.48% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 658917 | 0.44% | 200313 | 43.68% | 2018-06-30 |
| Franklin Biotechnology Discovery A | 660600 | 0.44% | -- | -- | 2018-06-30 |
| Met Invt Ser ClearBridge Agrsv Gr E | 499700 | 0.38% | -- | -- | 2018-03-31 |
| Schwab US Small-Cap ETF | 392029 | 0.30% | -- | -- | 2018-07-05 |
| Vanguard VIF Small Co Gr | 384630 | 0.29% | -66642 | -14.77% | 2018-03-31 |
| PowerShares Dynamic Biotech & Genome ETF | 620370 | 0.45% | -- | -- | 2018-05-24 |
| PRIMECAP Odyssey Aggressive Growth | 325000 | 0.24% | -- | -- | 2018-03-31 |
| TFS Market Neutral | 512563 | 0.59% | 512563 | -- | 2016-10-31 |
| Vanguard Market Neutral I | 320800 | 0.37% | -- | -- | 2016-09-30 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 219107 | 0.25% | 21189 | 10.71% | 2016-12-31 |
| Vanguard Health Care ETF | 174937 | 0.20% | -540 | -0.31% | 2016-12-31 |
| Schwab Total Stock Market Index | 174500 | 0.20% | -- | -- | 2016-12-31 |
| PrimeCap Odyssey Aggressive Growth Fund | 3857750 | 4.40% | -- | -- | 2015-09-30 |
| Pictet-Biotech | 1862712 | 2.30% | -550322 | -22.80% | 2014-09-30 |
| SPDR® S&P Biotech ETF | 1775008 | 2.40% | 5576 | 0.30% | 2015-11-27 |
| Vanguard Small Cap Index | 1705105 | 2.00% | 20962 | 1.20% | 2015-10-31 |
| Legg Mason CB US Aggressive Growth | 1509290 | 1.70% | -- | -- | 2015-10-31 |
| iShares Russell 2000 (AU) | 1412096 | 1.90% | -867 | -0.10% | 2015-11-27 |
| Fidelity Advisor® Biotechnology Fund | 1249451 | 1.40% | 67124 | 5.70% | 2015-10-31 |
| Vanguard Small Cap Growth Index Fund | 1039887 | 1.20% | -17914 | -1.70% | 2015-10-31 |
| Vanguard US Opportunities | 988679 | 1.10% | -- | -- | 2015-07-31 |
| Fidelity® Select Biotechnology Portfolio | 4827278 | 5.50% | 224224 | 4.90% | 2015-10-31 |
| Daniel M. Junius | Mr. Daniel M. Junius is an Independent Director at GlycoMimetics, Inc., an Independent Director at IDEXX Laboratories, Inc., a Chief Financial Officer at Deluxepinpoint Co. and a Treasurer & Director at Biotechnology Innovation Organization. He is on the Board of Directors at GlycoMimetics, Inc., IDEXX Laboratories, Inc., ImmunoGen, Inc. and Biotechnology Innovation Organization. Mr. Junius was previously employed as a Chief Financial Officer & Executive Vice President by New England Business Service, Inc. and a Chief Financial Officer & Vice President by Nashua Corp. He also served on the board at Vitae Pharmaceuticals, Inc. He received his undergraduate degree from Boston College and a graduate degree from Kellogg School of Management. |
|---|---|
| Howard H. Pien | Mr. Howard H. Pien is Chairman at Indivior Plc, Non-Executive Chairman at Juno Therapeutics, Inc., Chairman at Reckitt Benckiser Pharmaceuticals, Inc. and Chairman at Sapience Therapeutics, Inc. He is on the Board of Directors at ImmunoGen, Inc. Mr. Pien was previously employed as an Independent Director by SAGE Therapeutics, Inc., a Lead Independent Director by Ikaria, Inc., a Lead Independent Director by ViroPharma, Inc., Chairman, President & Chief Executive Officer by Medarex, Inc., an Independent Director by Vanda Pharmaceuticals, Inc., President, Chief Executive Officer & Director by Chiron Corp., a Lead Independent Director by ViroPharma, Inc., President-Pharmaceuticals International by GlaxoSmithKline Plc, a Principal by Abbott Laboratories, Vice President by Merck & Co., Inc., and President-Pharmaceuticals Operations by Smithkline Beecham Plc. He also served on the board at Talon Therapeutics, Inc., Arresto BioSciences, Inc., Bellerophon Therapeutics, Inc., Biotechnology Innovation Organization, Childrens Hospital Oakland, Pharmaceutical Research & Manufacturers of America, The Fox Chase Cancer Center, UCSF Benioff Children's Hospital Oakland and ViroPharma, Inc. He received his undergraduate degree from Massachusetts Institute of Technology and an MBA from Carnegie Mellon University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论